Dan Leonard
Stock Analyst at UBS
(3.90)
# 607
Out of 5,131 analysts
313
Total ratings
54.49%
Success rate
8.76%
Average return
Main Sectors:
Stocks Rated by Dan Leonard
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Neutral | $395 → $370 | $323.37 | +14.42% | 13 | Feb 10, 2026 | |
| IQV IQVIA Holdings | Maintains: Buy | $280 → $240 | $166.94 | +43.76% | 19 | Feb 6, 2026 | |
| TECH Bio-Techne | Maintains: Buy | $70 → $79 | $59.93 | +31.82% | 13 | Feb 5, 2026 | |
| RGEN Repligen | Maintains: Buy | $190 → $200 | $136.44 | +46.58% | 1 | Jan 16, 2026 | |
| A Agilent Technologies | Maintains: Buy | $170 → $180 | $125.81 | +43.07% | 23 | Nov 25, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $13 → $14 | $18.12 | -22.74% | 7 | Nov 7, 2025 | |
| BRKR Bruker | Maintains: Neutral | $40 → $43 | $36.51 | +17.78% | 12 | Nov 4, 2025 | |
| GH Guardant Health | Maintains: Buy | $80 → $110 | $104.85 | +4.91% | 11 | Oct 30, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Neutral | $500 → $590 | $504.82 | +16.87% | 18 | Oct 23, 2025 | |
| EXAS Exact Sciences | Maintains: Neutral | $61 → $53 | $103.24 | -48.66% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $15 | $6.62 | +126.59% | 10 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $300 → $305 | $428.03 | -28.74% | 2 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $225 | $212.58 | +5.84% | 18 | Jul 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $1,530 → $1,350 | $1,360.95 | -0.80% | 9 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $256.56 | +20.83% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $355 → $310 | $257.05 | +20.60% | 20 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $145 → $115 | $96.03 | +19.75% | 2 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $122 → $99 | $100.52 | -1.51% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $29 → $25 | $9.20 | +171.74% | 7 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $250 → $185 | $161.35 | +14.66% | 6 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $9 | $8.37 | +7.53% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $23.43 | +49.38% | 4 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $200 | $116.81 | +71.22% | 16 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $11 | $2.96 | +271.62% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $70 | $206.23 | -66.06% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $7 | $16.04 | -56.36% | 2 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $260 | $93.00 | +179.57% | 5 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $160 → $145 | $206.87 | -29.91% | 10 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $90 | $75.06 | +19.91% | 12 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $59 → $61 | $50.41 | +20.25% | 3 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $330 → $340 | $282.63 | +20.30% | 11 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $16.01 | +49.91% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $45 → $35 | $4.49 | +679.51% | 12 | Aug 14, 2019 |
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $395 → $370
Current: $323.37
Upside: +14.42%
IQVIA Holdings
Feb 6, 2026
Maintains: Buy
Price Target: $280 → $240
Current: $166.94
Upside: +43.76%
Bio-Techne
Feb 5, 2026
Maintains: Buy
Price Target: $70 → $79
Current: $59.93
Upside: +31.82%
Repligen
Jan 16, 2026
Maintains: Buy
Price Target: $190 → $200
Current: $136.44
Upside: +46.58%
Agilent Technologies
Nov 25, 2025
Maintains: Buy
Price Target: $170 → $180
Current: $125.81
Upside: +43.07%
10x Genomics
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $14
Current: $18.12
Upside: -22.74%
Bruker
Nov 4, 2025
Maintains: Neutral
Price Target: $40 → $43
Current: $36.51
Upside: +17.78%
Guardant Health
Oct 30, 2025
Maintains: Buy
Price Target: $80 → $110
Current: $104.85
Upside: +4.91%
Thermo Fisher Scientific
Oct 23, 2025
Maintains: Neutral
Price Target: $500 → $590
Current: $504.82
Upside: +16.87%
Exact Sciences
Aug 7, 2025
Maintains: Neutral
Price Target: $61 → $53
Current: $103.24
Upside: -48.66%
Aug 7, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $6.62
Upside: +126.59%
Jul 29, 2025
Downgrades: Sell
Price Target: $300 → $305
Current: $428.03
Upside: -28.74%
Jul 23, 2025
Maintains: Buy
Price Target: $240 → $225
Current: $212.58
Upside: +5.84%
May 20, 2025
Upgrades: Buy
Price Target: $1,530 → $1,350
Current: $1,360.95
Upside: -0.80%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $256.56
Upside: +20.83%
May 2, 2025
Maintains: Buy
Price Target: $355 → $310
Current: $257.05
Upside: +20.60%
May 1, 2025
Upgrades: Buy
Price Target: $145 → $115
Current: $96.03
Upside: +19.75%
Apr 7, 2025
Maintains: Overweight
Price Target: $122 → $99
Current: $100.52
Upside: -1.51%
Jan 17, 2025
Downgrades: Neutral
Price Target: $29 → $25
Current: $9.20
Upside: +171.74%
Jan 17, 2025
Downgrades: Neutral
Price Target: $250 → $185
Current: $161.35
Upside: +14.66%
Oct 18, 2024
Maintains: Neutral
Price Target: $7 → $9
Current: $8.37
Upside: +7.53%
Dec 7, 2023
Initiates: Neutral
Price Target: $35
Current: $23.43
Upside: +49.38%
Aug 10, 2023
Maintains: Neutral
Price Target: $225 → $200
Current: $116.81
Upside: +71.22%
Aug 8, 2023
Maintains: Neutral
Price Target: $14 → $11
Current: $2.96
Upside: +271.62%
Aug 4, 2023
Reiterates: Outperform
Price Target: $70
Current: $206.23
Upside: -66.06%
Feb 15, 2023
Reiterates: Underperform
Price Target: $7
Current: $16.04
Upside: -56.36%
Aug 25, 2022
Initiates: Neutral
Price Target: $260
Current: $93.00
Upside: +179.57%
Feb 4, 2022
Maintains: Equal-Weight
Price Target: $160 → $145
Current: $206.87
Upside: -29.91%
Feb 3, 2022
Maintains: Overweight
Price Target: $95 → $90
Current: $75.06
Upside: +19.91%
Dec 14, 2021
Maintains: Equal-Weight
Price Target: $59 → $61
Current: $50.41
Upside: +20.25%
Dec 14, 2021
Maintains: Overweight
Price Target: $330 → $340
Current: $282.63
Upside: +20.30%
Aug 10, 2021
Initiates: Overweight
Price Target: $24
Current: $16.01
Upside: +49.91%
Aug 14, 2019
Maintains: Hold
Price Target: $45 → $35
Current: $4.49
Upside: +679.51%